vs
Amneal Pharmaceuticals, Inc.（AMRX）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
Rithm Capital Corp.的季度营收约是Amneal Pharmaceuticals, Inc.的1.1倍（$828.2M vs $722.5M），Rithm Capital Corp.净利率更高（13.2% vs 10.8%，领先2.4%），Rithm Capital Corp.同比增速更快（508.5% vs 3.9%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs -17.9%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
AMRX vs RITM — 直观对比
营收规模更大
RITM
是对方的1.1倍
$722.5M
营收增速更快
RITM
高出504.6%
3.9%
净利率更高
RITM
高出2.4%
10.8%
两年增速更快
AMRX
近两年复合增速
-17.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $828.2M |
| 净利润 | $78.0M | $109.5M |
| 毛利率 | 44.3% | — |
| 营业利润率 | — | 29.9% |
| 净利率 | 10.8% | 13.2% |
| 营收同比 | 3.9% | 508.5% |
| 净利润同比 | 217.0% | 27.7% |
| 每股收益（稀释后） | $0.19 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRITM
| Q1 26 | $722.5M | $828.2M | ||
| Q4 25 | $814.3M | $1.5B | ||
| Q3 25 | $784.5M | $1.1B | ||
| Q2 25 | $724.5M | $1.2B | ||
| Q1 25 | $695.4M | $768.4M | ||
| Q4 24 | $730.5M | $2.1B | ||
| Q3 24 | $702.5M | $619.5M | ||
| Q2 24 | $701.8M | $1.2B |
净利润AMRXRITM
| Q1 26 | $78.0M | $109.5M | ||
| Q4 25 | $35.1M | $85.0M | ||
| Q3 25 | $2.4M | $221.5M | ||
| Q2 25 | $22.4M | $311.7M | ||
| Q1 25 | $12.2M | $78.8M | ||
| Q4 24 | $-31.1M | $290.2M | ||
| Q3 24 | $-156.0K | $121.7M | ||
| Q2 24 | $6.0M | $235.6M |
毛利率AMRXRITM
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
营业利润率AMRXRITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | 13.8% | 13.8% | ||
| Q3 25 | 9.0% | 21.4% | ||
| Q2 25 | 15.4% | 25.2% | ||
| Q1 25 | 14.4% | 7.4% | ||
| Q4 24 | 10.4% | 23.8% | ||
| Q3 24 | 12.6% | 7.3% | ||
| Q2 24 | 13.6% | 23.6% |
净利率AMRXRITM
| Q1 26 | 10.8% | 13.2% | ||
| Q4 25 | 4.3% | 5.7% | ||
| Q3 25 | 0.3% | 20.0% | ||
| Q2 25 | 3.1% | 25.6% | ||
| Q1 25 | 1.8% | 10.3% | ||
| Q4 24 | -4.3% | 14.0% | ||
| Q3 24 | -0.0% | 19.7% | ||
| Q2 24 | 0.9% | 19.2% |
每股收益（稀释后）AMRXRITM
| Q1 26 | $0.19 | $0.12 | ||
| Q4 25 | $0.10 | $0.09 | ||
| Q3 25 | $0.01 | $0.35 | ||
| Q2 25 | $0.07 | $0.53 | ||
| Q1 25 | $0.04 | $0.07 | ||
| Q4 24 | $-0.10 | $0.50 | ||
| Q3 24 | $0.00 | $0.20 | ||
| Q2 24 | $0.02 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $9.1B |
| 总资产 | — | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRITM
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $1.8B | ||
| Q3 25 | $201.2M | $1.6B | ||
| Q2 25 | $71.5M | $1.6B | ||
| Q1 25 | $59.2M | $1.5B | ||
| Q4 24 | $110.6M | $1.5B | ||
| Q3 24 | $74.0M | $1.6B | ||
| Q2 24 | $43.8M | $1.2B |
总债务AMRXRITM
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $35.4B | ||
| Q3 25 | $2.6B | $32.2B | ||
| Q2 25 | $2.2B | $31.2B | ||
| Q1 25 | $2.2B | $32.2B | ||
| Q4 24 | $2.4B | $32.6B | ||
| Q3 24 | $2.4B | $29.6B | ||
| Q2 24 | $2.4B | $30.1B |
股东权益AMRXRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $-70.8M | $8.4B | ||
| Q3 25 | $-109.5M | $8.5B | ||
| Q2 25 | $-112.1M | $7.9B | ||
| Q1 25 | $-131.7M | $7.8B | ||
| Q4 24 | $-109.3M | $7.8B | ||
| Q3 24 | $-93.4M | $7.7B | ||
| Q2 24 | $-57.5M | $7.3B |
总资产AMRXRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $3.7B | $53.1B | ||
| Q3 25 | $3.6B | $47.2B | ||
| Q2 25 | $3.4B | $44.3B | ||
| Q1 25 | $3.4B | $45.3B | ||
| Q4 24 | $3.5B | $46.0B | ||
| Q3 24 | $3.5B | $42.3B | ||
| Q2 24 | $3.5B | $42.0B |
负债/权益比AMRXRITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
